Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+breast cancer (BC): A network meta-analysis (NMA).

被引：1
|
作者：
Pelizzari, Giacomo
Gerratana, Lorenzo
Basile, Debora
Bartoletti, Michele
Lisanti, Camilla
Garattini, Silvio Ken
Bortot, Lucia
Corvaja, Carla
Buriolla, Silvia
Curtolo, Gianluca
Garutti, Mattia
Di Nardo, Paola
Torrisi, Elena
Da Ros, Lucia
Freschi, Andrea
Saracchini, Silvana
Bolzonello, Silvia
Miolo, Gianmaria
Spazzapan, Simon
Puglisi, Fabio
机构：
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, Udine, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, UOC Oncol, Rome, Italy
[4] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, Rome, Italy
[5] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, Aviano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
577
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer
    Yu, Anthony F.
    Singh, Jasmeet C.
    Wang, Rui
    Liu, Jennifer E.
    Eaton, Anne
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2017, 22 (06): : 642 - 647
  • [42] Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy.
    Lin, Po-Han
    Tsai, Li-Wei
    Lo, Chiao
    Kuo, Sung-Hsin
    Huang, Chiun-Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Stanowicka-Grada, Malwina
    Senkus, Elzbieta
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
  • [44] Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study
    Iwase, Toshiaki
    Nithya, Sridhar
    Kai, Megumi
    Willey, Jie
    Dong, Wenli
    Shen, Yu
    Krishnamurthy, Savitri
    Lucci, Anthony
    Le-Petross, H. T. Carisa
    Nasrazadani, Azadeh
    Saleem, Sadia
    Layman, Rachel
    Valero, Vicente
    Tripathy, Debu
    Woodward, Wendy
    Cheng, Yee Chung
    Nakhlis, Faina
    Bellon, Jennifer
    Lynce, Filipa
    Ueno, Naoto
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Genomics of HER2+breast cancer
    Perou, C.
    CANCER RESEARCH, 2022, 82 (04)
  • [46] Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+breast cancer patients with prior anti-HER2 therapy
    Im, S-A
    Bang, Y-J
    Oh, D-Y
    Giaccone, G.
    Bauer, T.
    Nordstrom, J.
    Li, H.
    Moore, P.
    Hong, S.
    Baughman, J.
    Rock, E.
    Burris, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [47] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Malwina Stanowicka-Grada
    Elżbieta Senkus
    Current Treatment Options in Oncology, 2023, 24 : 1633 - 1650
  • [48] circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+breast cancer patients
    Ling, Yun
    Liang Gehao
    Liu, Zihao
    Tian, Zhenluan
    Zhong, Wenjing
    Lin, Wanyi
    Chang, Gong
    CANCER RESEARCH, 2020, 80 (04)
  • [49] The Effect of HER2 Amplification in HER2+Breast Cancer
    Lee, M. K.
    Hurvitz, S. A.
    Tran, B. N.
    Fu, Y.
    Chung, D. U.
    Gornbein, J.
    Apple, S. K.
    Chang, H. R.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S45 - S45
  • [50] FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
    Gaibar, Maria
    Novillo, Apolonia
    Romero-Lorca, Alicia
    Malon, Diego
    Anton, Beatriz
    Moreno, Amalia
    Fernandez-Santander, Ana
    PHARMACEUTICS, 2022, 14 (02)
12345